Results of cutting-edge surgery in stage IIIA-N2 nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 21, Issue 2, 2009, Pages 105-109

  Rocco, Gaetano ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NONE   (Italy)

Author keywords

Lung cancer; N2 nonsmall cell lung cancer; Neoadjuvant treatment; Surgery

Indexed keywords

PLATINUM DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDIASTINUM LYMPH NODE; METASTASIS; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL MORTALITY; SURVIVAL RATE; THORACOTOMY; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PULMONARY SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 62349113173     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283210476     Document Type: Review

References (41)

1. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of nonsmall cell lung cancer-stage IUA: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007; 132:2433-2653. Updated guidelines on IIIA-N2 NSCLC on the basis of careful revisitation of current literature. Four main subsets of N2 disease are identified and their treatment outlined. Surgery is recommended as primary treatment modality for occult N2 disease. For N2 identified before thoracotomy, a multimodality approach is recommended without resorting to surgery outside properly designed clinical trials.
2. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000; 18:2981-2989.
3. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 2008; 86:362-367. The fate of completely resected, unexpected N2 patients receiving adjuvant chemotherapy. Involvement of multiple nodal stations was confirmed to be a negative survival prognosticator.
4. Riquet M, Bagan P, Le Pimpec Barthes F, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg 2007; 84:1818-1824. The knowledge of the lymphatic drainage is of paramount importance to understand the biology of N2 disease and to plan the surgical treatment of favorable subsets.
5. Ohta Y, Shimizu Y, Minato H, et al. Results of initial operations in non-small cell lung cancer patients with single-level N2 disease. Ann Thorac Surg 2006; 81:427-433.
6. Massard G, Ducrocq X, Kochetkova EA, et al. Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg 2006; 30:164-167.
7. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IHA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008; 86:912-920. Thirty-seven percent of the patients sent to neoadjuvant treatment are referred back for surgical treatment. Of these, roughly one-third undergo complete resection. The 5-year survival rates can exceed a remarkable 47%.
8. Uy KL, Darling G, Xu W, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 134:188-193. 'The price to pay' to achieve an effective neoadjuvant treatment in N2 disease.
9. Venuta F, Anile M, Diso D, et al. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg 2007; 31:714-717. Retrospective review of surgical resections following neoadjuvant treatment with a remarkable rate of parenchyma-saving resection.
10. Van Schil P. Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg 2008; 135:718-719. Pneumonectomy remains well tolerated after induction chemotherapy. The addition of radiotherapy may substantially increase the operative risks.
11. Mansour Z, Kochetkova EA, Santelmo N, et al. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann Thorac Surg 2008; 86:228-233. The aspect of the surgical treatment of residual N2 disease after induction is consistently approached in this manuscript.
12. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 nonsmall-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006; 94:1099-1106.
13. Cerfolio RJ. Editorial comment to 9. Eur J Cardiothorac Surg 2007; 31:717-718. The real issue: the extent of parenchymal resection after induction treatment. Between the need to avoid pneumonectomy and the goal of achieving complete resection.
14. Daly BDT, Fernando HC, Ketcedjian A, et al. Pneumonectomy after radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg 2006; 82:227-231.
15. Pass HI. Lung cancer staging techniques and induction therapy: maybe timing is everything. J Clin Oncol 2008; 26:3306-3307. A valuable insight in the potential role and sequence of mediastinoscopy, PET, and EBUS in the re-staging process following induction treatment for locally advanced lung cancer.
16. van Meerbeeck JP, Kramer GW, Van Schil PE, et al., European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 nonsmall-cell lung cancer. J Natl Cancer Inst 2007; 99:442-450. A well devised multidisciplinary approach aimed at designing the best method of local control of primary tumor after neoadjuvant treatment. The conclusions have caused a debate, which is still ongoing.
17. De Waele M, Hendriks J, Lauwers P, et al. Nodal status at repeat mediastinoscopy determines survival in nonsmall cell lung cancer with mediastinal nodal involvement treated by induction therapy, Eur J Cardiothorac Surg 2006; 29:240-243.
18. Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. Ann Thorac Surg 2007; 83:1826-1830. The intriguing concept of a noninvasive way of predicting mediastinal nodal involvement is developed in this manuscript.
19. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006; 24:3333-3339.
20. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006; 131:1229-1235.
21. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer, J Clin Oncol 2008; 26:3543-3551. Contribution full of potential implications for future NSCLC management strategies.
22. Vansteenkiste J, Betticher D, Eberhardt W, De Leyn P. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 nonsmall cell lung cancer. J Thorac Oncol 2007; 2:684-685. A meticulous analysis of the methodological pitfalls of the EORTC trial. Interesting observation of a fairly homogeneous 5-year survival between 30 and 36% in the available series of postinduction surgical treatment of N2 disease.
23. Leo F, De Pas T, Catalano G, et al. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer. J Natl Cancer Inst 2007; 99:1210.
24. De Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for nonsmall cell lung cancer. Eur J Cardiothorac Surg 2007; 32:1-8.
25. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in nonsmall cell lung cancer. Eur J Cardiothorac Surg 2006; 30:787-792.
26. Kuzdzal J, Zielinski M, Papla B, et al. The transcervical extended mediastinal lymphadenectomy versus cervical mediastinoscopy in nonsmall cell lung cancer staging. Eur J Cardiothorac Surg 2007; 31:88-94.
27. Bordoni R. Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 2008; 13:945-953.
28. Gudbjartsson T, Gyllstedt E, Pikwer A, Jönsson P. Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy. Ann Thorac Surg 2008; 86:376-382. Important surgical series because it supports the lack of correlation between chemoradiation and postpneumonectomy (especially right-sided) morbidity.
29. Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125:254-260.
30. Yokomise H, Gotoh M, Okamoto T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 133:1179-1185. How many surgeons would consider primary surgery in these patients?
31. Albain KS, Swann RS, Rusch V, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IMA (pN2) nonsmall-cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 RTOG 9309. J Clin Oncol 2005; 23 (Suppl):624s. [abstract #7014].
32. Keller SM, Vangel MG, Wagner H, et al. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg 2004; 128:130-137.
33. Doddoli C, Barlesi F, Trousse D, et al. One hundred consecutive pneumonectomies after induction therapy for nonsmall cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 2005; 130:416-425.
34. Dooms C, Verbeken E, Stroobants S, et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008; 26:1128-1134. An in-depth analysis of the issues related with the use of the combination of PET-CT scan for postinduction staging.
35. Garrido P, Gonzalez-Larriba JL, Insa A, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IUA (N2) and HIB (T4NO-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007; 25:4736-4742. The fundamental impact of complete resection echoes in this multicentric study, which selects the patients' age and the completeness of response as determinant survival prognosticators.
36. Van Schil P, Van Meerbeeck J, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005; 26:192-197.
37. Goldstraw P. Selection of patients for surgery after induction chemotherapy for N2 non-small-cell lung cancer. J Clin Oncol 2006; 24:3317-3318.
38. Wright G, Manser RL, Byrnes G, et al. Surgery for nonsmall cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006; 61:597-603.
39. Zhong W, Yang X, Bai J, et al. Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable nonsmall cell lung cancer. Eur J Cardiothorac Surg 2008; 34:187-195. The demonstration of the importance of complete mediastinal lymphadenectomy to remove skip metastases and occult deposits which are the most favorable manifestation of stage IIIA-N2 NSCLC.
40. Johnson DH, Rusch VW, Turrisi AT. Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99:415-418. Lucid analysis of the spectrum of therapeutic possibilities for locally advanced NSCLC weighing the pros and cons of each single option.
41. Turrisi AT. Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer. J Clin Oncol 2005; 23:4827-4829.